Patents by Inventor Susanne Bredenberg
Susanne Bredenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10736838Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.Type: GrantFiled: April 5, 2019Date of Patent: August 11, 2020Assignee: Emplicure ABInventors: Håkan Engqvist, Susanne Bredenberg, Anders Petterson, Thomas Lundqvist, Anna Dahlgren, Anders Sågström
-
Patent number: 10543203Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.Type: GrantFiled: March 9, 2017Date of Patent: January 28, 2020Assignee: Emplicure ABInventors: Susanne Bredenberg, Anna Dahlgren, Anders Sågström, Håkan Engqvist
-
Publication number: 20190282494Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.Type: ApplicationFiled: April 5, 2019Publication date: September 19, 2019Inventors: Håkan Engqvist, Susanne Bredenberg, Anders Petterson, Thomas Lundqvist, Anna Dahlgren, Anders Sågström
-
Patent number: 10251834Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.Type: GrantFiled: September 5, 2011Date of Patent: April 9, 2019Assignee: EMPLICURE ABInventors: Håkan Engqvist, Susanne Bredenberg, Anders Pettersson, Thomas Lundqvist, Anna Dahlgren, Anders Sågström
-
Publication number: 20180049976Abstract: A transdermal drug administration device comprising a drug delivery element attached to a solvent-swellable and/or solvent-soluble substrate, wherein the drug delivery element defines a contact surface for location, in use, against a patient's skin. The drug delivery element comprises an active pharmaceutical ingredient and a porous solid material.Type: ApplicationFiled: March 9, 2016Publication date: February 22, 2018Applicant: EMPLICURE ADInventors: Susanne BREDENBERG, Bing CAl, Hakan ENGQVIST, Wei XIA
-
Publication number: 20170239229Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.Type: ApplicationFiled: March 9, 2017Publication date: August 24, 2017Inventors: Susanne BREDENBERG, Anna DAHLGREN, Anders SÅGSTRÖM, Håkan ENGQVIST
-
Patent number: 9622972Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterized in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.Type: GrantFiled: March 2, 2010Date of Patent: April 18, 2017Assignee: Emplicure ABInventors: Susanne Bredenberg, Anna Dahlgren, Anders Sågström, Håkan Engqvist
-
Patent number: 9597281Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: GrantFiled: April 25, 2013Date of Patent: March 21, 2017Assignee: Orexo ABInventors: Anders Pettersson, Christer Nystrom, Susanne Bredenberg
-
Patent number: 9265720Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: GrantFiled: October 26, 2005Date of Patent: February 23, 2016Assignee: Orexo ABInventors: Anders Pettersson, Christer Nyström, Susanne Bredenberg
-
Publication number: 20130273119Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.Type: ApplicationFiled: September 5, 2011Publication date: October 17, 2013Applicant: OREXO ABInventors: Häkan Engqvist, Susanne Bredenberg, Anders Pettersson, Thomas Lundqvist, Anna Dahlgren, Anders Sågström
-
Publication number: 20130230589Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: ApplicationFiled: April 25, 2013Publication date: September 5, 2013Applicant: Orexo ABInventors: Anders Pettersson, Christer Nystrom, Susanne Bredenberg
-
Publication number: 20120277261Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: ApplicationFiled: February 22, 2012Publication date: November 1, 2012Applicant: Orexo ABInventors: Anders Pettersson, Christer Nystrom, Susanne Bredenberg
-
Publication number: 20120015007Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.Type: ApplicationFiled: March 2, 2010Publication date: January 19, 2012Applicant: OREXO ABInventors: Susanne Bredenberg, Anne Dahlgren, Anders Sagstrom, Hakan Engqvist
-
Publication number: 20110268796Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: ApplicationFiled: July 15, 2011Publication date: November 3, 2011Applicant: OREXO ABInventors: Anders Pettersson, Christer Nyström, Susanne Bredenberg
-
Publication number: 20080311208Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: ApplicationFiled: October 26, 2005Publication date: December 18, 2008Inventors: Anders Pettersson, Christer Nystrom, Susanne Bredenberg
-
Publication number: 20060216352Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition includes an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially insoluble or sparingly soluble in water, in combination with a bioadhesion and/or mucoadhesion promoting agent adhered to the surfaces of the carrier particles. The composition is primarily intended for sublingual or intranasal administration. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: January 15, 2004Publication date: September 28, 2006Applicant: OREXO ABInventors: Christer Nystrom, Susanne Bredenberg